Amino-bisphosphonates

Amino-bisphosphonates has been studied in 1 paper since 2021: 1 observational study in people. The newest paper, Aug 19, 2021: “The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on amino-bisphosphonates

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“the incidence of COVID-19 hospitalization, intensive care unit (ICU) utilization, and COVID-19 potentially related mortality were similar in N-BPs-treated and nontreated subjects.”
The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) OutcomesJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2021doi:10.1002/jbmr.4419

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Humans1

What did studies of amino-bisphosphonates find?

2

Studies of amino-bisphosphonates measured 2 outcomes: COVID-19 potentially related mortality and COVID-19 hospitalization.

COVID-19 potentially related mortality

no changein humans1

1 study
  1. Amino-bisphosphonates were not clearly linked with COVID-19 potentially related mortality in humans (Compared with nonusers).

    HumansCompared with nonusers

COVID-19 hospitalization

no changein humans1

1 study
  1. Amino-bisphosphonates were not clearly linked with COVID-19 hospitalization in humans (Compared with nonusers) (Incidence 12.32 (95% CI 9.61–15.04) versus 11.55 (95% CI 8.91–14.20) in users and nonusers).

    HumansCompared with nonusers

Latest